Baroda BNP Paribas Health and Wellness Fund
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
Growthvine rating: 1/5 — ranked #84 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹10.45 (as of 2026-10-01) |
|---|
| AUM | ₹507 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ankeet Pandya |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −11.93% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 77.3% of NIFTY Pharma's upside and 124.7% of its downside.
Market cap allocation
| Large cap | 32.4% |
|---|
| Mid cap | 45.0% |
|---|
| Small cap | 22.6% |
|---|
Concentration
| Top 5 holdings | 37.2% |
|---|
| Top 10 holdings | 59.8% |
|---|
| Total holdings | 33 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 9.0%
- Divis Laboratories Ltd. — 8.0%
- Torrent Pharmaceuticals Ltd. — 8.0%
- Ipca Laboratories Ltd. — 6.2%
- Lupin Ltd — 6.0%
- Laurus Labs Limited — 5.7%
- Apollo Hospitals Enterprises Ltd. — 5.4%
- Fortis Healthcare Ltd — 4.5%
- AstraZeneca Pharma India Ltd. — 3.6%
- Glenmark Pharmaceuticals ltd — 3.4%
Top sectors
- Pharma & Biotech — 74.6%
- Healthcare — 19.5%
- Miscellaneous — 2.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 10.5% | Q1 (Top) | #16 of 76 |